

IN THE CLAIMS

Please amend claims 4-6 and 11-12 as indicated below.

Please add new claims 15-20 as indicated below.

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method for diagnosing cancer, which comprises detecting a soluble GPC3 protein in a test sample.
2. (Original) The method for diagnosing cancer of claim 1, wherein the soluble GPC3 protein is a N-terminal peptide of GPC3.
3. (Original) The method for diagnosing cancer of claim 2, wherein the N-terminal peptide of GPC3 is a peptide fragment contained in an amino acid sequence of GPC3 consisting of the 1st amino acid to the 374th amino acid, or an amino acid sequence of GPC3 consisting of the 1st amino acid to the 358th amino acid.
4. (Currently Amended) The diagnosis method of ~~any one of claims 1 to 3~~ claim 1, wherein the test sample is selected from the group consisting of blood, serum and plasma.
5. (Currently Amended) The diagnosis method of ~~any one of claims 1 to 4~~ claim 1, wherein the cancer is hepatic cancer.
6. (Currently Amended) The method of ~~any one of claims 1 to 5~~ claim 1, comprising using an anti-GPC3 antibody.
7. (Original) The method of claim 6, comprising using an anti-GPC3 antibody immobilized on a carrier and an anti-GPC3 antibody labeled with a labeling substances.

8. (Original) The method of claim 7, wherein the labeling substances are biotin.
9. (Original) A diagnostic reagent for cancer, comprising an anti-GPC3 antibody.
10. (Original) The diagnostic reagent of claim 9, comprising an anti-GPC3 antibody immobilized on a carrier and an antibody labeled with a labeling substance.
11. (Currently Amended) The diagnostic reagent of claim 9 ~~or 10~~, wherein the cancer is hepatic cancer.
12. (Currently Amended) The diagnostic reagent of ~~any one of claims 9 to 11~~ claim 9, wherein the anti-GPC3 antibody recognizes the N-terminal peptide of GPC3.
13. (Original) A diagnostic kit, comprising an anti-GPC3 antibody.
14. (Original) The diagnostic kit of claim 13, comprising the anti-GPC3 antibody immobilized on carriers, and an antibody labeled with a labeling substance.
15. (New) The diagnosis method of claim 3, wherein the test sample is selected from the group consisting of blood, serum and plasma.
16. (New) The diagnosis method of claim 3, wherein the cancer is hepatic cancer.
17. (New) The diagnosis method of claim 4, wherein the cancer is hepatic cancer.
18. (New) The method of claim 3, comprising using an anti-GPC3 antibody.
19. (New) The diagnostic reagent of claim 10, wherein the cancer is hepatic cancer.
20. (New) The diagnostic reagent of any one of claim 11, wherein the anti-GPC3 antibody recognizes the N-terminal peptide of GPC3.